@article{079ed4572bda49ccac3969fb27c7724c,
title = "A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: Compiled by the Pregnancy and Non-Communicable Diseases Committee of FIGO (the International Federation of Gynecology and Obstetrics)",
keywords = "management, mean arterial pressure, monitoring, noncommunicable diseases, placental growth factor, pre-eclampsia, prediction, risk stratification, second trimester, soluble fms-like tyrosine kinase-1, third trimester, timed delivery, uterine artery pulsatility index",
author = "Poon, {Liona C.} and Magee, {Laura A.} and Stefan Verlohren and Andrew Shennan and {von Dadelszen}, Peter and Eyal Sheiner and Eran Hadar and Gerard Visser and {Da Silva Costa}, Fabricio and Anil Kapur and Fionnuala McAuliffe and Amala Nazareth and Muna Tahlak and Kihara, {Anne B.} and Hema Divakar and McIntyre, {H. David} and Vincenzo Berghella and Huixia Yang and Roberto Romero and Nicolaides, {Kypros H.} and Nir Melamed and Moshe Hod",
note = "Funding Information: This project was funded by unrestricted educational grants from PerkinElmer Inc., Waltham, USA; Roche Diagnostics International Ltd, Rotkreuz, Switzerland; and Thermo Fisher Scientific, Hennigsdorf, Germany. Funding Information: Relating to the submitted work, Liona Poon reports receipt of a Health and Medical Research Fund grant to assess the role of pro‐ and antiangiogenic markers for pre‐eclampsia in the second and third trimester (Project No: 136168059), and a grant from Roche Diagnostics for the Asia PROGNOSIS study. Outside the submitted work, LP reports honoraria for lectures from Roche Diagnostics, Ferring Pharmaceuticals, and GE Healthcare; nonfinancial support of in‐kind contributions for research from Roche Diagnostics, PerkinElmer Inc., Thermo Fisher Scientific, and GE Healthcare, and personal fees for consultancy from Roche Diagnostics and Ferring Pharmaceuticals. Outside the submitted work, Stefan Verlohren reports personal fees from Roche Diagnostics, Thermo Fisher Scientific, and Alexion. Outside the submitted work, Fabricio da Silva Costa reports research support from PerkinElmer Inc., and personal fees from Roche Diagnostics and Thermo Fisher Scientific. Outside the submitted work, Kypros H. Nicolaides reports being Director of the Fetal Medicine Foundation. All other authors report no actual or potential conflicts of interest. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = jul,
doi = "10.1002/ijgo.13763",
language = "English",
volume = "154",
pages = "3--31",
journal = "International Journal of Gynecology and Obstetrics",
issn = "0020-7292",
publisher = "Elsevier",
number = "S1",
}
